Watchlist for December 20, 2007

See one of the recent 'Chart Reading' posts for some potential swing candidates.

Potential day trades:

(From Briefing.com)

Gapping Down

In reaction to weak earnings/guidance: RAD -14.6%, RUTH -13.8%, XING -12.5%, LDK -12.3% (also downgraded to Sell at Piper Jaffray), LEG -5.4%, PAYX -5.2%, HWAY -4.1%... Other news: MBI -18.6% (bond risk soars as co discloses CDO-squared exposure; credit-default swaps climb 110 bps to 590 bps- Bloomberg), ARRY -18.3% (announces phase 2 study shows no apparent difference in efficacy between AZD6244 and temozolomide for the primary endpoint), ALTU -17.0% (reacquires ALTU-238 global development and commercialization rights, also downgraded to Market Perform at Wachovia), PRST -15.5% (provides update regarding delayed quarterly filing of Form 10-Q for Q3 2007; also announced the SEC is conducting an informal inquiry), INGN -13.7% (plans to expand biomarker database in Phase 3 trials and file BLA and MAA for Advexin), FOLD -9.5% (announces positive results from phase 2 clinical trials of Amigal for Fabry Disease), NFI -8.2% (announces management changes), IDEV -7.8% (receives non-approvable letter from FDA for Valstar), GFI -3.3% (says overall attributable production for Q2 F2008 is expected to be down approximately 3.5% YoY), MICC -2.9% (still checking), TRID -1.5% (announces resignation of CFO), STI -1.2% (its 8-K discloses additional write-downs in Q4)... Analyst downgrades: PCLN -2.9% (downgraded to Hold at Stifel), ATLS -1.5% (downgraded to Outperform at Friedman Billings), FBCM -1.0% (downgraded to Hold at Jefferies), HES -1.0% (downgraded to Hold at Citigroup).

Gapping Up

In reaction to strong earnings/guidance: VOL +20.6%, PIR +11.4%, MLHR +9.1% (also announces $200 mln share repurchase program), ORCL +6.5%, SCS +5.6% (also announces $250 mln share repurchase program), CAG +4.9%, ATVI +4.9%, ACN +4.7%, SMOD +3.7%, NKE +2.7%... M&A news: ECHO +108.1% (INTU to acquire ECHO for $17/share)... Other news: CNIC +20.4% (entered into a non-binding letter of interest with a third party), CGEN +18.6% (announces it has signed a collaborative discovery and license agreement with Roche), CNLG +17.6% (estimates 3-year backlog at over $4.5 mln, highest backlog of orders since the introduction of its new products), LOCM +8.0% (announces a strategic partnership with Citysearch), TSS +5.5% (will replace Synovus Financial (SNV) in the S&P 500 on 12/31), CRGN +4.9% (names Sean Cassidy as CFO), NVAX +4.7% (announces favorable interim results from Phase I/IIa Trial), CT +4.3% (announces $1.90/share special cash dividend), SLM +3.5% (says it and Citibank have amended the terms of the contracts so that there will be no trigger prices), LMC +2.9% (still checking), FDRY +2.8% (will replace Andrew (ANDW) in the S&P MidCap 400), RIMM +2.6% (still checking), ANPI +2.3% (authorized to begin Phase I trial of Multistem), NLY +2.2% (announces Q4 dividend 30% increase), RIO +1.8% (in talks with Tata Steel for plant in Brazil - Business Standard), ETN +1.8% (agrees to acquire The Moeller Group and launches tender offer to acquire Phoenixtec Power), WPO +1.7% (will replace Temple-Inland (TIN) in the S&P 500 on 12/28), GM +1.7% (Navistar to buy GM truck unit - WSJ), SNCR +1.2% (announces organizational changes), PZZA +1.1% (Cramer makes positive comments on MadMoney), PDX +1.1% (announces $100 mln share repurchase program), BIG +1.1% (WSJ mentions as appealing to corporate buyers due to their valuations), QRCP +1.1% (provides guidance and New Ventures update)... Analyst upgrades: PBR +2.6% (upgraded to Buy at Citigroup), MA +2.2% (upgraded to Outperform at Bear Sterns), CLWR +2.1% (initiated with Buy at Stanford Financial), WYNN +1.9% (upgraded to Neutral at UBS), LULU +1.9% (initiated with Buy at ThinkEquity), SNCR +1.3% (hearing upgraded to Buy at tier-1 firm), DRI +1.0% (upgraded to Outperform at Morgan Keegan).

Disclaimer & How I use this list